Literature DB >> 371629

Comparison of gastrointestinal effects of aspirin and fenoprofen. A double blind crossover study.

S M Chernish, B D Rosenak, R L Brunelie, R Crabtree.   

Abstract

Sixteen men received 3904 mg of aspirin, 2400 mg of fenoprofen, or placebo daily for 1 week in a double blind and crossover trial. Fecal blood loss was measured by 51Cr labeled red cells; gastric and duodenal pathology were observed endoscopically. There was more (P less than 0.05) blood loss (4.96 ml) after aspirin than after fenoprofen (2.46 ml) or placebo (0.79 ml). By endoscopic examination, aspirin induced more (P less than 0.05) gastrointestinal pathology than fenoprofen or placebo, and there was a correlation of 0.70 between the two methods used in this study.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371629     DOI: 10.1002/art.1780220410

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

1.  Placebo-controlled comparison of piroxicam-beta-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans.

Authors:  L Santucci; S Fiorucci; S Chiucchiù; A Sicilia; L Bufalino; A Morelli
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

2.  A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects.

Authors:  F L Lanza
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

3.  Antiprostaglandin synthetase activity of nonsteroidal anti-inflammatory drugs and gastrointestinal micro-bleeding: a comparison of flurbiprofen with benoxaprofen.

Authors:  A C Yeung Laiwah; T E Hilditch; P W Horton; J A Hunter
Journal:  Ann Rheum Dis       Date:  1981-10       Impact factor: 19.103

Review 4.  Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies.

Authors:  F L Lanza; J D Arnold
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.